Netscientific Share Discussion Threads

[blakieboy7] 09/5/2023 11:22

PDSB has been been creeping up again pre ASCO. Worth following the share price if you're invested in NSCI

[loafofbread] 02/5/2023 17:36

Lovely 50k delayed buy at 77p just posted. Looks like someone excited by the Glycotest update!

[kingston78] 02/5/2023 13:37

It is great that a subsidiary can raise money from other investors. Normally, the top holding company raises money and loans to its subsidiaries. This just goes on to show that there is attraction in NSCI's portfolio companies that external investors are interested to be acquiring a minority stake. This actually paves the way in crystallising the valuation of the subsidiary at this stage of development.

[blakieboy7] 02/5/2023 07:19

RNS Glycotest fundraiser

[blakieboy7] 27/4/2023 13:44

We are pleased to present updated data from the VERSATILE-002 clinical trial," stated Lauren V. Wood, M.D., PDS Biotech's Chief Medical Officer and a co-author of the study. "The incidence of HPV-positive head and neck cancers is growing rapidly, and there is currently a lack of effective targeted therapies to address this population. The ASCO meeting provides an opportunity to share promising early data with the clinical and scientific community that shows how PDS0101 combined with KEYTRUDA® can potentially address this unmet medical need."

[blakieboy7] 27/4/2023 13:41

- PDS Biotech To Present Updated Data At 2023 American Society Of Clinical Oncology Annual Meeting Highlighting Combination Of PDS0101 And KEYTRUDA In Head And Neck Cancer Patients

[kingston78] 25/4/2023 12:23

I am most impressed and excited about NSCI acquiring a 30% shareholding in Deeptech Recycling Technologies Limited as announced by the company.

- 30 per cent. direct holding - the company acquired for an undisclosed amount from administration the majority of the assets of Recycling Technologies (a business that had targeted an AIM IPO in Q1 of 2022 at a pre-money valuation of c. GBP60 million). Our Value Creation team is working on relaunching this business in the rapidly growing plastics waste management space.

In my opinion, NSCI could not have paid much for its stake. Waste recycling is a big and growing business. The previous owner must have been ambitious in trying to float the business but maybe due to lack of interest, support and money to launch it. Timing and circumstances are important. There is a chance that NSCI will succeed in floating this business or sell its stake on at significant gain.

[kingston78] 24/4/2023 11:28

There is more trading activity today, which is far more than previous weeks.

[blakieboy7] 24/4/2023 10:10

Nice start to the week

[blakieboy7] 21/4/2023 18:23

PDSB UP 7% currently too

[loafofbread] 21/4/2023 17:54

Positive end to the week.

[investordave] 18/4/2023 21:15

Thanks for that.

[loafofbread] 18/4/2023 18:47

ID,

Delayed buy trade for 37,000 just posted which equals todays sells.

(or bed and Isa of some sort)

[blakieboy7] 18/4/2023 17:51

Still way undervalued

[investordave] 18/4/2023 17:08

This share price has shown some resilience today which is great to see.

[kingston78] 17/4/2023 10:45

On 7th June 2021 almost two years ago the share price spiked to an intra day high of 209 p.

Share prices go in cycle as nature intends, in wave form, often over-extended either to the upside or to the downside.

I have studied NSCI's share chart using different time scales. I am convinced that they are currently all bullish.

No one knows what the future holds, but I guess that current management is working on exit strategies in crystallising substantial gains on one or more of its portfolio companies.

Investors Chronicle suggests that a conservative valuation per share is more than 160 p. I will go further than that. All brokers in the US are rating a strong buy for PDSB with a target of US$20 in a year's time (now US$6.9 a share with a market cap US$212 million). NSCI holds 4.4% of PDSB (US$9.3 million currently). This element alone illustrates how the British stock market has under-values NSCI.

[blakieboy7] 14/4/2023 14:20

PDSB up 5% pre market

[kingston78] 14/4/2023 09:48

I have extracted the salient points from the Company's recent announcement. In my opinion, given an opportunity, any one of the portfolio companies might have fetched a higher valuation on its own than NSCI as a whole.

Highlights of 2022

-- Including EMV Capital, its VC firm, the Group now has a portfolio of 24 companies.
-- The Group expects a significant increase in Fair Value as at 31 December 2022.
-- Across the Group's portfolio, an aggregate amount of c.GBP70 million was raised through equity and venture debt by 18 companies.

-- The Group's 'capital light' investment model saw it make modest direct equity investments of c.GBP0.6 million, together with GBP5.3 million of third party 'advised' investments in which it has a carried interest, across 11 portfolio companies.

-- A short-term proprietary trade profit of GBP0.3 million on facilitating the sale of a GBP0.5 million position in a portfolio company, highlighting the Group's intention to move progressively to a more 'evergreen' investment model, and an ability to generate liquidity in private company investments.

-- Fees generated by EMV Capital covered the majority of its costs, whilst providing infrastructure and services to the Group and its portfolio companies.

-- H2 2022 saw a marked increase in activity, with several portfolio companies achieving significant operational milestones and key fundraisings.

-- Strengthened Board to drive strategic growth ambitions, and key strategic hires to expand and deepen transactional and portfolio management capabilities.

-- Final results for the year to 31 December 2022 expected to be announced by the end of May 2023.


Portfolio highlights of 2022

During the period, a number of the Group's portfolio companies raised growth financing and made substantial progress on their business plans. Key highlights include:

-- ProAxsis Limited - 100 per cent. direct holding - the company won further pharma services contracts and grant support for its new products programme, and entered into key R&D collaborations. In February 2023, the company secured a GBP500,000 funding facility from AB Group.

-- Glycotest, Inc. - 62 per cent. direct stake - the company closed a $1.46 million convertible loan facility with Fosun Pharma lending $500,000.

-- PDS Biotech Inc. (NASDAQ:PDSB) - 4.4 per cent. direct holding - this immunotherapy for oncology company made substantial clinical progress across four Phase 2 clinical trials and secured a $35 million venture debt facility during the second half of the year. Since year end, the company has completed an in-licensing deal with Merck KGaA, and announced plans for a Phase 3 trial.

-- Q-Bot Limited - 19.3 per cent. direct holding and a further 33.8 per cent. advised holding - EMV Capital syndicated a GBP2.8 million fundraising for working capital, scale-up production of robots, and engagement with growing UK and international demand.

-- Sofant Technologies Ltd - 1.8 per cent. direct holding and a further 27.2 per cent. advised holding - EMV Capital syndicated and led a GBP4.2 million fundraising. The company has made significant progress towards commercial launch, including a further joint development agreement with a global player, and reaching technical milestones.

-- DName-iT Holdings Limited - 46 per cent. direct holding (through Cetromed subsidiary). EMV Capital syndicated a first close of GBP147,000 as part of a GBP500,000 equity fundraising programme. This spin-out from Belgium's University of Leuven has developed a powerful proprietary technology that provides quality assurance throughout genetic testing processes for clinical laboratories.

Since the year end a number of other portfolio companies have announced further positive news including EpiBone's progress in clinical trials and FOx Biosystems raising EUR5.8 million.

New investments

During the period the Group introduced three new investments into the portfolio utilising its 'capital light' investment model:

-- Vortex Biotech Holdings Limited - 30 per cent. direct holding - the company (one we previously advised but with no direct holding), continued its progress in creating Centres of Excellence for pharma services around Circulating Tumour Cells.

-- Ventive Limited - 16 per cent. direct holding - EMV Capital led a GBP2.5 million financing package including equity and debt matched funding that unlocked a c.GBP1.5m BEIS grant, receiving its stake in partial settlement of fees. The company's business lines include a passive air ventilation system used by schools and a modular heat pump for newbuild residential applications.

-- Deeptech Recycling Technologies Limited - 30 per cent. direct holding - the company acquired for an undisclosed amount from administration the majority of the assets of Recycling Technologies (a business that had targeted an AIM IPO in Q1 of 2022 at a pre-money valuation of c. GBP60 million). Our Value Creation team is working on relaunching this business in the rapidly growing plastics waste management space.

[loafofbread] 14/4/2023 09:22

Talk about using the system to hide the buys today.

Just let it run ffs.

[loafofbread] 13/4/2023 23:46

A no brainer that we would get a decent IC update.

Even better for PDSB to finally get it's mojo back.

This should really get us back towards a £1.00 and then some.

Still think PDSB is $30+ this year.

[blakieboy7] 13/4/2023 18:19

PDSB 12% up now

[kingston78] 13/4/2023 16:38

Thanks to Blakeboy7. I have read the IC brief summary, which continues to recommend a strong buy as the directly owned portfolio asset was worth 140 p a share and the EM's carried interest was worth a further 21 p a share.

Referring to the latest company announcement that indicated a significant uplift in the valuation, I would not be surprised that one or more of its portfolio companies are ripe for IPO or trade sale. That will crystallise in cash terms of the hidden gem in the Group as a whole.

[blakieboy7] 13/4/2023 16:17

Or just Google search this and then click the link - "two valuation anomalies that are worth exploiting investors chronicle"

[blakieboy7] 13/4/2023 16:16

If you copy the link and paste into your browser it should work- did for me anyway

[blakieboy7] 13/4/2023 16:15

Kingston, the link I posted is not gated